Abstract:Emerging evidence supports a causal role of microglial dysfunction in the pathogenesis of Alzheimer's disease (AD). The triggering receptor expressed on myeloid cells 2 (TREM2) is a microglial surface receptor genetically linked to the risk for AD. TREM2 undergoes proteolytic cleavage releasing a soluble variant termed soluble TREM2 (sTREM2). The cerebrospinal fluid (CSF) levels of sTREM2 track the progression of AD and are positively correlated with neuronal injury markers including the CSF levels of total tau and phospho-tau. However, the physiological and pathological functions of sTREM2 remain unknown. To gain insights into the roles of sTREM2 in AD, we expressed sTREM2 in the brain of 5xFAD amyloid model mice by an AAV-mediated approach or by direct stereotaxic injection of recombinant sTREM2 protein. The effects of sTREM2 on microglial activity, Aβ pathology, spatial memory and synaptic plasticity were assessed. To address the impact of sTREM2 on microglial function, we assessed the effects of recombinant sTREM2 protein on microglial survival and responsiveness on inflammatory stimuli. We further explored the underlying signaling pathway and analyzed the effects of AD risk-associated mutations on sTREM2 function. We found that sTREM2 induced microglial clustering around amyloid plaques, reduced Aβ pathology and improved cognitive and synaptic functions in 5xFAD mouse model. sTREM2 promoted microglial survival in a PI3K/Akt-dependent manner and stimulated the production of inflammatory cytokines depending on NF-κB. Variants of sTREM2 carrying AD risk-associated mutations were less effective in both suppressing apoptosis and triggering inflammatory responses. Our study supports a protective role of sTREM2 against amyloid pathology and related synaptic and cognitive deficits by modulating microglial functions, and suggests that sTREM2 can be explored for AD therapy.

TREM2 Regulates Innate Immunity in Alzheimer’s Disease

Opposing Roles of the Triggering Receptor Expressed on Myeloid Cells 2 and Triggering Receptor Expressed on Myeloid Cells-Like Transcript 2 in Microglia Activation.

TREM2 in Alzheimer’s Disease

TREM2 in Alzheimer's Disease: Microglial Survival and Energy Metabolism.

TREM2 Ectodomain and Its Soluble Form in Alzheimer’s Disease

TREM2 is a Receptor for Β-Amyloid That Mediates Microglial Function

TREM2 and the Progression of Alzheimer’s Disease

The Emerging Roles and Therapeutic Potential of Soluble TREM2 in Alzheimer's Disease.

TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models

TREMs in Alzheimer's disease: Genetic and clinical investigations.

TREM2-Dependent Effects on Microglia in Alzheimer's Disease

TREMs in Alzheimer's Disease: Genetic and Clinical Investigations

TREM2 in CNS Homeostasis and Neurodegenerative Disease

Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of Alzheimer's disease.

The Emerging Roles and Therapeutic Potential of Soluble TREM2 in Alzheimer’s Disease

Recent Advances in Triggering Receptor Expressed in Myeloid 2 and Its Role in Alzheimer's Disease

TREM2 signalling as a multifaceted player in brain homoeostasis and a potential target for Alzheimer's disease treatment

Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?

O4‐02‐01: SOLUBLE TREM2 MODULATES MICROGLIAL FUNCTION AND PROTECTS AGAINST AMYLOID PATHOLOGY

Amyloid-beta Modulates Microglial Responses by Binding to the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2).

Contributions of Triggering-Receptor-expressed-on-myeloid-cells-2 to Neurological Diseases